Live Analyst Rating Changes 1505 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Roanna Ruiz
LP
Roanna Ruiz
Leerink Partners
Wall Street Analyst
★★★☆☆
#1411
on 13Foresight · ranked by our own returns
59%
Success Rate
+7.8%
Average Return
13 of 22 calls profitable · -3.7% vs benchmark
📈 Across the calls we could measure, roughly 59% of Roanna Ruiz's ratings turned a profit when each position was held for 1 year — averaging +7.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

47 Buy 6 Hold 0 Sell
Roanna's Stock Coverage 23 ratings · 2026-06-18
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
UTHR
United Therapeutics
 Jun 12, 2026 BUY Buy
-20.4% avg upside
26 analysts
$700.00
26.94% Upside
 +1.0%
VIR
Vir Biotechnology
 May 27, 2026 BUY Strong Buy
+182.3% avg upside
16 analysts
 — -5.4%
AQST
Aquestive Therapeutics
 May 15, 2026 BUY Strong Buy
+100.1% avg upside
10 analysts
$9.00
103.07% Upside
 +3.2%
IBIO
Ibio
 May 15, 2026 BUY Strong Buy
+262.3% avg upside
11 analysts
$6.00
274.93% Upside
 +0.0%
CRMD
Cormedix
 May 15, 2026 BUY Strong Buy
+72.9% avg upside
13 analysts
$15.00
73.02% Upside
 +13.1%
MNKD
MannKind
 Feb 25, 2026 BUY Buy
+79.6% avg upside
22 analysts
 — -5.4%
CYTK
Cytokinetics
 Jan 13, 2026 BUY Strong Buy
+9.9% avg upside
36 analysts
 — +24.7%
TRVI
Trevi Therapeutics
 Nov 18, 2025 BUY Strong Buy
+22.4% avg upside
16 analysts
$16.00
2.18% Downside
 +25.6%
ENTA
Enanta Pharmaceuticals
 Oct 01, 2025 HOLD Buy
+160.1% avg upside
17 analysts
$9.00
28.82% Downside
 +12.2%
HK:2137
Brii Biosciences Limited
 Aug 25, 2025 HOLD Hold
+96.1% avg upside
1 analyst
$2.00
96.10% Upside
 ·
AKBA
Akebia Therapeutics
 Aug 22, 2025 BUY Strong Buy
+864.1% avg upside
16 analysts
$7.00
586.23% Upside
 -70.7%
LNTH
Lantheus
 Aug 22, 2025 BUY Strong Buy
-27.6% avg upside
20 analysts
$99.00
4.07% Downside
 +79.8%
XERS
Xeris Pharmaceuticals
 Aug 20, 2025 BUY Strong Buy
+33.3% avg upside
10 analysts
$9.00
30.53% Upside
 -8.8%
SPRY
ARS Pharmaceuticals
 Aug 14, 2025 BUY Strong Buy
+119.1% avg upside
12 analysts
$28.00
182.83% Upside
 -48.6%
NAMS
NewAmsterdam Pharma Company
 Aug 07, 2025 BUY Strong Buy
+54.8% avg upside
18 analysts
$44.00
45.84% Upside
 +29.9%
LXRX
Lexicon Pharmaceuticals
 Aug 07, 2025 HOLD Buy
+98.8% avg upside
9 analysts
$1.00
50.94% Downside
 +70.5%
ARDX
Ardelyx
 Aug 05, 2025 BUY Strong Buy
+132.3% avg upside
21 analysts
$11.00
88.37% Upside
 +8.0%
AMRN
Amarin
 Jul 31, 2025 HOLD Buy
-47.2% avg upside
18 analysts
$10.00
36.50% Downside
 +8.6%
A
Agilent
 Mar 06, 2025 BUY Strong Buy
+5.4% avg upside
32 analysts
 — -8.3%
AVIR
Atea Pharmaceuticals
 May 14, 2024 HOLD Buy
+50.1% avg upside
6 analysts
$4.00
7.66% Downside
 -35.6%
ALGS
Aligos Therapeutics
 May 07, 2024 HOLD Strong Buy
+765.6% avg upside
11 analysts
$25.00
367.19% Upside
 -77.9%
CORT
Corcept Therapeutics
 Jan 22, 2024 HOLD Buy
-46.3% avg upside
15 analysts
$23.00
71.95% Downside
 +150.6%
CFRXQ
ContraFect
 Dec 20, 2022 HOLD Buy
+10969999900.0% avg upside
10 analysts
$80.00
7999999899.97% Upside
 ·
🔒 18 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Roanna Ruiz — Frequently Asked Questions
How accurate are Roanna Ruiz's stock ratings?
Based on the calls 13Foresight could measure, about 59% of Roanna's ratings were profitable over a one-year hold, with an average return of +8.1% per rating, or -3.4% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Roanna ranked on 13Foresight?
Roanna Ruiz is currently ranked #1411 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Roanna cover?
Roanna most recently has ratings on UTHR, VIR, AQST, IBIO, CRMD, MNKD, CYTK, TRVI, ENTA, HK:2137, AKBA, LNTH and 11 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.